GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Cash Flow from Financing Activities | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr | ₹-445 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
Year | Cash Flow from Financing Activities |
---|---|
Mar2024 | ₹-3,906 Cr |
Mar2023 | ₹-77 Cr |
Mar2022 | ₹-520 Cr |
Mar2021 | ₹-442 Cr |
Mar2020 | ₹-445 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
Years | Cash Flow from Financing Activities | % Change | |
---|---|---|---|
Mar2024 | ₹-3,906 Cr | Negative | |
Mar2023 | ₹-77 Cr | Negative | |
Mar2022 | ₹-520 Cr | Negative | |
Mar2021 | ₹-442 Cr | Negative | |
Mar2020 | ₹-445 Cr | - |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹40,810.4 Cr | 3.7% | 5% | 40.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹417,400.0 Cr | -0.3% | 3.1% | 13.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹164,844.0 Cr | 3.5% | 11% | 63.5% | Stock Analytics | |
CIPLA | ₹121,328.0 Cr | 1.6% | 2.7% | 11.6% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,521.0 Cr | 4.1% | 4.4% | 24.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,043.0 Cr | 6.8% | 11.3% | 3.1% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 3.7% |
5% |
40.9% |
SENSEX | 2.7% |
11.8% |
14% |
You may also like the below Video Courses